PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23220162-9 2013 The hydroxyproline content, the number of fibroblasts, the mRNA expression level of IL-2 and TGF-beta1 in 0.1mg/ml FK506 group were significantly less than those of 0.05 mg/ml FK506 group, 0.01 mg/ml FK506 group and control group. Tacrolimus 115-120 interleukin 2 Rattus norvegicus 84-88 29454984-6 2018 Interferon (IFN)-gamma and IL-2 content in the serum were lower after operation (P < .05) in the AdOX40Ig and FK506 groups. Tacrolimus 113-118 interleukin 2 Rattus norvegicus 27-31 27386875-8 2016 Moreover, the cortical mRNA and serum protein expression levels of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) were decreased in FK506 group, especially at 6 h and at 1 day after TBI. Tacrolimus 139-144 interleukin 2 Rattus norvegicus 67-80 27386875-8 2016 Moreover, the cortical mRNA and serum protein expression levels of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) were decreased in FK506 group, especially at 6 h and at 1 day after TBI. Tacrolimus 139-144 interleukin 2 Rattus norvegicus 82-86 27102446-7 2016 At day 12, a new subcutaneous injection of tacrolimus-loaded microspheres was performed and two days after injection, tacrolimus plasma levels were again increased and both IL-2 plasma levels and PP2B activity decreased. Tacrolimus 43-53 interleukin 2 Rattus norvegicus 173-177 25647147-11 2015 Immunohistochemistry showed that, after tacrolimus treatment, the expressions of nuclear factor of activated T cell and interleukin 2 were downregulated in submucosal fibroblasts, neovascular cells, and glandular cells. Tacrolimus 40-50 interleukin 2 Rattus norvegicus 120-133 25647147-12 2015 CONCLUSIONS: This study suggests that low-dose systemic tacrolimus has a preventive effect on laryngotracheal stenosis by inhibiting the activation of immune cells in the injured airway mucosa via the calcineurin/nuclear factor of activated T cell/interleukin 2 pathway. Tacrolimus 56-66 interleukin 2 Rattus norvegicus 248-261 12389075-7 2002 Unsurprisingly, both cyclosporin A and tacrolimus significantly inhibited IL-2 and IL-2Rbeta at both time points. Tacrolimus 39-49 interleukin 2 Rattus norvegicus 74-78 20128966-6 2010 RESULTS: High dose of FK506 resulted in the immunosuppressed in LT rats, as evident by low production of IL-2 and IFN-gamma, and without liver rejection compared to rats in the control group. Tacrolimus 22-27 interleukin 2 Rattus norvegicus 105-109 19728359-6 2009 FK506 also lowered the protein levels of TNFalpha and IL-2 in ischemic brain areas. Tacrolimus 0-5 interleukin 2 Rattus norvegicus 54-58 16410063-4 2006 In experimental animals, tacrolimus (FK506) was injected every day to inhibit the IL-2 production by helper T-cells. Tacrolimus 25-35 interleukin 2 Rattus norvegicus 82-86 16410063-4 2006 In experimental animals, tacrolimus (FK506) was injected every day to inhibit the IL-2 production by helper T-cells. Tacrolimus 37-42 interleukin 2 Rattus norvegicus 82-86 15047987-6 2004 Moreover, significant decrease in IL-2 secretion at 0.25, 0.5, 1 and 50 microM CsA and FK506 at concentrations of 100 and 1000 nM were observed. Tacrolimus 87-92 interleukin 2 Rattus norvegicus 34-38 19682688-8 2010 Western blotting demonstrated that tacrolimus decreased the expression of calcineurin, NFATc4, and IL-2 of cultured VSMCs. Tacrolimus 35-45 interleukin 2 Rattus norvegicus 99-103 11714196-4 2001 FK506, in a concentration-dependent fashion, inhibited T-cell proliferation and steady-state mRNA expression of IL-2 and IL-7; half-maximal suppression was obtained at 10(-7) to 5 x 10(-8) M. We tested whether FK506 antiproliferative effect could be overcome with exogenously reconstituted rIL-2 and/or rIL-7. Tacrolimus 0-5 interleukin 2 Rattus norvegicus 290-295 11150862-8 2001 Interleukin (IL)-2 and IL-2 receptor synthesis was upregulated in control animals and inhibited by tacrolimus treatment. Tacrolimus 99-109 interleukin 2 Rattus norvegicus 0-18 11150862-8 2001 Interleukin (IL)-2 and IL-2 receptor synthesis was upregulated in control animals and inhibited by tacrolimus treatment. Tacrolimus 99-109 interleukin 2 Rattus norvegicus 23-27 11918741-5 2002 RESULTS: FK506 treatment with 1.0 and 0.3 mg/kg body weight (BW) daily from day 1 to day 4 significantly reduced the glomerular expression of mRNA for interferon-gamma (IFN-gamma; 1.0 mg/kg BW FK506, 32.4% to the placebo group, P < 0.01) and IL-2 (55.6%, P < 0.01) on day 5. Tacrolimus 9-14 interleukin 2 Rattus norvegicus 245-249 11714196-8 2001 FK506 inhibited T-cell activation stimulated by rIL-2 and by rIL-7, individually and in combination. Tacrolimus 0-5 interleukin 2 Rattus norvegicus 48-53 22827197-1 1993 In vitro studies of FK506 demonstrated that the agent inhibited the T-cell receptormediated signal transduction that results in the transcription of interleukin 2. Tacrolimus 20-25 interleukin 2 Rattus norvegicus 149-162 10363590-8 1999 The percentage of detectable serum IL-2 level was 45% in the allograft control group, but was undetectable in groups treated with the most effective dose of tacrolimus or CyA at days 3 and 6 after grafting. Tacrolimus 157-167 interleukin 2 Rattus norvegicus 35-39 8784785-1 1996 BACKGROUND: The immunophilins are proteins that mediate actions of immunosuppressant drugs such as FK506 and cyclosporin A by binding to calcineurin, inhibiting its phosphatase activity, and increasing the phosphorylation level of transcription factors required for interleukin 2 formation. Tacrolimus 99-104 interleukin 2 Rattus norvegicus 266-279 9792034-6 1998 FK506 administration attenuated hepatic-mRNA expression of interleukin-2 and both superoxide anions as well as tumour necrosis factor-alpha production by hepatic macrophages, but did not change CD14-mRNA expression in Propionibacterium acnes-treated rats. Tacrolimus 0-5 interleukin 2 Rattus norvegicus 59-72 9792034-8 1998 FK506 seems to attenuate such activation by suppressing hepatic interleukin-2 expression, without affecting CD14 expression on the cells. Tacrolimus 0-5 interleukin 2 Rattus norvegicus 64-77 28976697-6 1998 FK506 administration attenuated hepatic-mRNA expression of interleukin-2 and both superoxide anions as well as tumour necrosis factor-alpha production by hepatic macrophages, but did not change CD14-mRNA expression in Propionibacterium acnes-treated rats. Tacrolimus 0-5 interleukin 2 Rattus norvegicus 59-72 28976697-8 1998 FK506 seems to attenuate such activation by suppressing hepatic interleukin-2 expression, without affecting CD14 expression on the cells. Tacrolimus 0-5 interleukin 2 Rattus norvegicus 64-77 8971291-12 1996 Water immersion stress increased gastric mucosal IL-1 beta and IL-2 contents 6 h after stress treatment, and these increases were prevented by FK506. Tacrolimus 143-148 interleukin 2 Rattus norvegicus 63-67 8906804-6 1996 While the addition of rIL-2 reversed the inhibitory effect of cyclosporin A and FK506, the addition of rIL-4, rIL-7, or rIFN-gamma did not, although these cytokines induced progression into the S phase of the cell cycle. Tacrolimus 80-85 interleukin 2 Rattus norvegicus 22-27 8822088-5 1996 FK506 treatment suppressed the accumulation of ED-1-positive cells, CD4-positive cells, CD8-positive cells, interleukin-2 (IL-2)-receptor-positive cells, leukocyte-function-associated antigen-1 (LFA-1)-positive cells and intercellular adhesion molecule-1 (ICAM-1)-expression in nephritic glomeruli. Tacrolimus 0-5 interleukin 2 Rattus norvegicus 123-127 8822088-5 1996 FK506 treatment suppressed the accumulation of ED-1-positive cells, CD4-positive cells, CD8-positive cells, interleukin-2 (IL-2)-receptor-positive cells, leukocyte-function-associated antigen-1 (LFA-1)-positive cells and intercellular adhesion molecule-1 (ICAM-1)-expression in nephritic glomeruli. Tacrolimus 0-5 interleukin 2 Rattus norvegicus 108-121 8822088-7 1996 On the other hand, IL-2 production from the spleen cells isolated from nephritic rats treated with FK506 was lower than that in the nephritic control rats. Tacrolimus 99-104 interleukin 2 Rattus norvegicus 19-23 8822088-8 1996 These results suggest that FK506 is effective against crescentic-type anti-GBM nephritis and that the antinephritic mechanisms of FK506 is due to the inhibition of intraglomerular accumulation and activation of leukocytes through the suppression of ICAM-1 expression and IL-2 production. Tacrolimus 130-135 interleukin 2 Rattus norvegicus 271-275 7539555-9 1995 Cellular expression of IL-1 alpha, IL-2, IL-6, gamma-INF, FGF, and TGF-beta mRNA was suppressed with FK506 to below isograft levels, and clinical rejection was not observed with the doses, routes, and schedules used. Tacrolimus 101-106 interleukin 2 Rattus norvegicus 35-39 1717008-7 1990 FK506 treatment resulted not only in the highest inhibition of expression of IL-2 receptors on T cells, but also in the prevention of the expression of MHC class II antigens on ocular resident cells. Tacrolimus 0-5 interleukin 2 Rattus norvegicus 77-81 1712484-1 1991 Investigations of the actions and interactions of the immunophilin ligands FK506, cyclosporin A (CsA), rapamycin, and 506BD suggest that complexes of FK506 with an FK506-binding protein or of CsA with a cyclophilin (CsA-binding protein) inhibit the T-cell receptor-mediated signal transduction that results in the transcription of interleukin 2. Tacrolimus 150-155 interleukin 2 Rattus norvegicus 331-344 1712484-1 1991 Investigations of the actions and interactions of the immunophilin ligands FK506, cyclosporin A (CsA), rapamycin, and 506BD suggest that complexes of FK506 with an FK506-binding protein or of CsA with a cyclophilin (CsA-binding protein) inhibit the T-cell receptor-mediated signal transduction that results in the transcription of interleukin 2. Tacrolimus 150-155 interleukin 2 Rattus norvegicus 331-344